NCT04962438

Brief Summary

Explore the effects of anti-VEGF targeted drugs on blood pressure and endothelial function in cancer patients.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
30

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Jul 2019

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 5, 2019

Completed
2 years until next milestone

First Submitted

Initial submission to the registry

June 27, 2021

Completed
18 days until next milestone

First Posted

Study publicly available on registry

July 15, 2021

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2021

Completed
29 days until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2021

Completed
Last Updated

July 15, 2021

Status Verified

June 1, 2021

Enrollment Period

2.4 years

First QC Date

June 27, 2021

Last Update Submit

July 4, 2021

Conditions

Cardiac ToxicityVEGFEndothelial Dysfunction

Keywords

Cardiac safetyanti-VEGF drugsEndothelial dysfunction

Outcome Measures

Primary Outcomes (1)

  • Time ending

    30 days after using the Anti-VEGF Targeted Drugs

    1 month

Study Arms (1)

Tumor patients using anti-VEGF drugs

Drug: Anti-VEGF

Interventions

Anti-VEGFDRUG

Anti-tumor drugs targeting the vascular endothelial growth factor (VEGF) signaling pathway

Tumor patients using anti-VEGF drugs

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Thirty tumor patients selected for anti-VEGF drugs, demographic and clinical information of all patients were collected before chemotherapy, ambulatory blood pressure monitoring, endothelial function determination (PWV, EndoPAT)

You may qualify if:

  • Tumor patients using anti-VEGF drugs

You may not qualify if:

  • Hypertension, coronary heart disease, valvular heart disease, cardiomyopathy and other organic heart diseases, exclude liver and kidney failure, severe cerebrovascular disease, chronic obstructive pulmonary disease, rheumatic immune system disease

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Peking University Third Hospital

Beijing, Beijing Municipality, 100191, China

RECRUITING

MeSH Terms

Conditions

Cardiotoxicity

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular DiseasesPathologic ProcessesPathological Conditions, Signs and SymptomsDrug-Related Side Effects and Adverse ReactionsChemically-Induced DisordersRadiation InjuriesWounds and Injuries

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 27, 2021

First Posted

July 15, 2021

Study Start

July 5, 2019

Primary Completion

December 1, 2021

Study Completion

December 30, 2021

Last Updated

July 15, 2021

Record last verified: 2021-06

Locations

CN(1)